TICKERNERD
Menu
CDNACDNAHealthcare · Diagnostics & Research

CDNA Stock Forecast: CareDx, Inc. Price Predictions for 2026-2027

Last close, 14 Aug 2026
$45
−4.35% on the day

The 7 Wall Street analysts covering CareDx, Inc. hold a median 12-month price target of $52 — +14.7% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 100 of 100 as at 15 Aug 2026 — among the strongest tenth. Here, the model and the Street point the same way.

Market cap
$2.3B
Ticker Nerd rank
100 / 100
Median analyst target
$52
Analysts covering
7
Total return, dividends reinvested
1W
−2.9%
1M
+56.7%
YTD
+140.6%
1Y
+283.4%
From 52W high
−5.3%
From 52W low
+291.7%
$12
$48
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

CDNA stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores CareDx, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 15 Aug 2026
100 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Revisions
99
Quality
99
Issuance
95
Momentum
92
Value
89
Growth
76
Accruals
50
Volatility
48
Size
34

Revisions (99): Analysts have, on balance, been raising their forecasts.

Volatility (48): The share price moves around a lot.

Size (34): Larger than most of the companies we track — more scrutinised, less often mispriced.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

CDNA stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on CDNA, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$10$20$30$40$50$60$70Oct 25Jan 26Apr 26Jul 26CDNAHigh $64Median $52Low $40

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

What Wall Street says7 analysts
4 Buy3 Hold0 Sell
Low $40Median $52High $64

The green dot is the last close — the median target sits +14.7% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 3 moved their price target up and 0 moved it down.

DateFirmActionRatingTarget
6 Aug 2026BTIGMaintainsBuy$45 → $60
31 July 2026HC Wainwright & Co.ReiteratesNeutral$46
16 July 2026BTIGMaintainsBuy$28 → $45
16 July 2026BTIGMaintainsBuy—
29 Apr 2026BTIGMaintainsBuy$26 → $28
29 Apr 2026BTIGMaintainsBuy—
26 Feb 2026BTIGMaintainsBuy—
25 Feb 2026Wells FargoMaintainsEqual-Weight—
15 Dec 2025Wells FargoMaintainsEqual-Weight—
6 Nov 2025BTIGMaintainsBuy—
23 Sept 2025BTIGReiteratesBuy—
12 Sept 2025BTIGReiteratesBuy—
26 Aug 2025William BlairInitiatesMarket Perform—
8 Aug 2025Wells FargoMaintainsEqual-Weight—
18 July 2025Craig-HallumMaintainsBuy—
5 May 2025HC Wainwright & Co.ReiteratesNeutral—
5 May 2025Stephens & Co.ReiteratesOverweight—
17 Apr 2025Goldman SachsMaintainsBuy—
3 Mar 2025HC Wainwright & Co.MaintainsNeutral—
27 Feb 2025Stephens & Co.ReiteratesOverweight—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. CDNA appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Estimates

CDNA analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
EPS revision, 90 days
+29.9%
Analysts raising
0
Analysts cutting
0
Fundamentals

CareDx, Inc. (CDNA) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
21.8×

Cheaper than 36% of US stocks

Price / sales
5.1×

Cheaper than 25% of US stocks

Price / book
5.5×

Cheaper than 20% of US stocks

EV / EBITDA
168.6×

Cheaper than 1% of US stocks

Growth & margins
Revenue growth (YoY)
52.2%

Higher than 87% of US stocks

Earnings growth (YoY)
52.2%

Higher than 76% of US stocks

Gross margin
73.5%

Higher than 86% of US stocks

Operating margin
0.2%

Higher than 46% of US stocks

Net margin
24.2%

Higher than 85% of US stocks

Returns & dividend
Return on equity
29.5%

Higher than 87% of US stocks

Return on assets
−0.3%

Higher than 42% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

CDNA vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelDiagnostics & Research
CompanyMarket capTKN rank
CDNACareDx, Inc.$2.3B
100
WGSGeneDx Holdings Corp.$2.2B
47
NEONeoGenomics, Inc.$2.0B
76
GRALGRAIL, Inc.$3.0B
36
VCYTVeracyte, Inc.$3.3B
97
PSNLPersonalis, Inc.$1.5B
43
ADPTAdaptive Biotechnologies Corp.$4.0B
78

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own CareDx, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest CDNA news & analysis

CareDx Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Business Wire · 7 Aug 2026neutral

CareDx announced that on August 5, 2026, it awarded inducement grants to 35 new employees, consisting of restricted stock units for an aggregate of 97,090 shares of common stock, as an inducement material to their acceptance of employment. Most of the RSUs (93,090 shares across 34 employees) will vest over time.

Why it matters — CDNA watchers would care because the inducement grants reflect the company's hiring activity and its use of equity compensation under Nasdaq Listing Rule 5635(c)(4), which can affect share dilution.

CareDx Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Business Wire · 31 July 2026neutral

CareDx granted 15,822 shares of restricted stock units (RSUs) to newly appointed Executive Advisor James McNally as an inducement material to his employment, announced on July 30, 2026.

Why it matters — The grant signals the company's effort to attract and retain a new executive advisor, which may be of interest to CDNA watchers tracking leadership changes.

Why CareDx Stock Jumped Today

The Motley Fool · 31 July 2026positive

CareDx stock rose on the day following positive commentary about the company's role in improving transplant patient outcomes. The article noted that CareDx's non-invasive tests are in high demand.

Why it matters — The jump in stock price and strong demand for CareDx's non-invasive transplant tests signal positive momentum for the company's core business.

CareDx, Inc. (CDNA) Q2 2026 Earnings Call Transcript

Seeking Alpha · 31 July 2026neutral

Seeking Alpha published the transcript of CareDx's Q2 2026 earnings conference call, covering management's prepared remarks and Q&A with analysts.

Why it matters — The transcript provides a full record of how management discussed the company's quarterly performance and outlook, which CDNA watchers rely on for detail beyond the earnings release.

CareDx (CDNA) Beats Q2 Earnings and Revenue Estimates

Zacks Investment Research · 30 July 2026positive

CareDx reported Q2 earnings of $0.37 per share, beating the Zacks Consensus Estimate of $0.22 per share, and up from $0.10 per share a year earlier.

Why it matters — The earnings beat signals that CareDx's recent quarterly performance exceeded analyst expectations.

FAQ

Frequently asked questions about CDNA stock

What is the CDNA stock price forecast for 2026-2027?

The 7 Wall Street analysts covering CareDx, Inc. have a median 12-month price target of $52, with estimates ranging from $40 to $64. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is CDNA stock a buy right now?

Of the 7 analysts covering CareDx, Inc., 4 rate it a Buy, 3 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks CareDx, Inc. 100 out of 100 across roughly 4,600 US stocks as at 15 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank CDNA?

As at 15 Aug 2026, CareDx, Inc. ranks 100 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Revisions (99 of 100).

Will CDNA stock go up?

No one can know that. What the data says: the median 12-month target from 7 analysts implies +14.7% from the last close, and Ticker Nerd's factor model ranks CareDx, Inc. 100 out of 100 as at 15 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the CDNA stock forecast for 2030?

No analyst covering CareDx, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for CDNA are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $40 to $64 over the next 12 months.

How has CDNA stock performed over the past year?

CareDx, Inc. returned +283.4% over the 12 months to 14 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does CareDx, Inc. do?

CareDx Inc. is a leading precision medicine company that discovers, develops, and commercializes clinically differentiated diagnostic solutions for transplant patients and caregivers.

What is the latest news on CDNA?

The most recent item we track (Business Wire, 7 Aug 2026): "CareDx Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)". CareDx announced that on August 5, 2026, it awarded inducement grants to 35 new employees, consisting of restricted stock units for an aggregate of 97,090 shares of common stock, as an inducement material to their acceptance of employment. Most of the RSUs (93,090 shares across 34 employees) will vest over time.

Company

About CareDx, Inc.

CareDx Inc. is a leading precision medicine company that discovers, develops, and commercializes clinically differentiated diagnostic solutions for transplant patients and caregivers. It specializes in genomics-based testing services, including AlloSure Kidney and AlloSure Heart for donor-derived cell-free DNA surveillance in kidney and heart transplant patients, AlloMap Heart as a gene expression test for heart transplants, and AlloSure Lung for lung transplants. The company also provides high-quality lab products like HLA typing solutions such as AlloSeq Tx, Olerup SSP, and AlloSeq cfDNA to improve donor-recipient matching for organs and stem cells. Complementing these, CareDx Inc. offers digital transplant solutions through platforms like Ottr for patient surveillance and EMR integration, XynManagement for quality improvement and care coordination, and mobile apps such as AlloCare and Transplant Hero for medication adherence and health monitoring. Operating primarily in the healthcare sector with a focus on testing services, products, patient solutions, and pharma services, CareDx Inc. supports transplant centers, clinicians, and biopharma partners across the pre- and post-transplant journey. Founded in 1998 and headquartered in Brisbane, California, it plays a key role in advancing transplant outcomes through non-invasive molecular testing and innovative technologies.

CEO Mr. John Walter Hanna Jr. · 761 employees · United States · https://caredx.com